Announcing Positive Results of Saturn-2 Phase 3 Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

Revolutionizing treatment for patients in need

Scroll To Discover
Young woman smiling. Young woman smiling. Young woman smiling.

About

We’re committed to delivering boundless therapeutic ingenuity

Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company that embodies the values of commitment, empowerment, and teamwork. We aim to bring novel therapeutics to patients across a range of diseases with limited treatment options.

Pipeline

Novel therapies, beginning with the eye

For the millions of patients living with Demodex blepharitis, an FDA-approved treatment is on the horizon.

News & Media

Here is the latest from Tarsus

09/27/2022 Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
09/07/2022 Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis
08/11/2022 Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields

Opt-in
This field is for validation purposes and should be left unchanged.